ChromaDex Corporation (NASDAQ:CDXC) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET
Company Participants
Ben Shamsian - Vice President, Lytham Partners
Rob Fried - Chief Executive Officer
James Lee - Interim Chief Financial Officer
Andrew Shao - Senior Vice President of Scientific and Regulatory Affairs
Conference Call Participants
Mitch Pinheiro - Sturdivant
Bill Dezellem - Titan
Sean McGowan - ROTH MKM Partners
Jeffrey Mark - Farmhouse Equity Research
Howard Horberg - Horberg Enterprises
Operator
Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corporation's Second Quarter of 2024 Earnings Conference Call. My name is Dustin, and I will be the conference operator today. At this time all participants’ are in a listen-only mode. And as a reminder, this conference call is being recorded. This afternoon, ChromaDex issued a news release announcing the company's financial results for the second quarter of 2024. If you have not reviewed this information, both are available within the Investor Relations section of ChromaDex's website at www.chromadex.com.
I would now like to turn the conference call over to Ben Shamsian, Vice President of Lytham Partners. Please go ahead, Mr. Shamsian.
Ben Shamsian
Thank you, and good afternoon, and welcome to ChromaDex Corporation's second quarter of 2024 results investor call. With us today are ChromaDex's Chief Executive Officer, Rob Fried; Interim Chief Financial Officer, James Lee; Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao; and Vice President of Finance, Leslie Yu. Dr. Shao and Mr. Yu will join the call for Q&A.
Today's conference call may include forward-looking statements, including statements related to ChromaDex's research and development and clinical trial plans and the timing and results of set trials, the timing of future regulatory filings, the expansion of the sale of Niagen products and ingredients in new markets, business development opportunities, future financial results, cash needs, operating performance, investor interest and business prospects and opportunities, as well as anticipated results of operations.
Forward-looking statements represent only the company's estimates on the date of this conference call and are not intended to give any assurance as to actual future results. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties. Many factors could cause ChromaDex's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements.
These risk factors include those contained in ChromaDex's quarterly report on Form 10-Q most recently filed with the SEC, including results of operations, financial condition, cash flows as well as global market and economic conditions on our business. Please note, the company assumes no obligation to update any forward-looking statements after the date of this conference call to conform with forward-looking statements actual results or to changes in its expectations. In addition, certain financial information presented in this call references non-GAAP financial measures.